Literature DB >> 18923010

Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping.

Burkhard Springer1, Romana C Calligaris-Maibach, Claudia Ritter, Erik C Böttger.   

Abstract

We determined the quantitative levels and the genetic mechanisms of resistance in drug-resistant clinical isolates of Mycobacterium tuberculosis sampled over a period of 3 years (n = 45; 17 of the isolate were multidrug resistant). Our results led us to hypothesize that some strains categorized as resistant to isoniazid, ethambutol, or streptomycin by standard laboratory procedures of in vitro drug susceptibility testing may still respond to a treatment regimen that includes these agents.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18923010      PMCID： PMC2593253          DOI： 10.1128/JCM.01114-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  20 in total

1.  Fitness cost of chromosomal drug resistance-conferring mutations.

Authors:  Peter Sander; Burkhard Springer; Therdsak Prammananan; Antje Sturmfels; Martin Kappler; Michel Pletschette; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Drug-resistant tuberculosis.

Authors:  E C Böttger
Journal:  Lancet       Date:  2001-04-21       Impact factor: 79.321

Review 3.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

4.  Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis.

Authors:  Paolo Miotto; Federica Piana; Daniela Maria Cirillo; Giovanni Battista Migliori
Journal:  J Clin Microbiol       Date:  2007-10-31       Impact factor: 5.948

5.  Multicenter evaluation of ethambutol susceptibility testing of mycobacterium tuberculosis by agar proportion and radiometric methods.

Authors:  B Madison; B Robinson-Dunn; I George; W Gross; H Lipman; B Metchock; A Sloutsky; G Washabaugh; G Mazurek; J Ridderhof
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

6.  Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis.

Authors:  Michelle H Larsen; Catherine Vilchèze; Laurent Kremer; Gurdyal S Besra; Linda Parsons; Max Salfinger; Leonid Heifets; Manzour H Hazbon; David Alland; James C Sacchettini; William R Jacobs
Journal:  Mol Microbiol       Date:  2002-10       Impact factor: 3.501

7.  High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.

Authors:  M H Cynamon; Y Zhang; T Harpster; S Cheng; M S DeStefano
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

8.  Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands.

Authors:  D van Soolingen; P E de Haas; H R van Doorn; E Kuijper; H Rinder; M W Borgdorff
Journal:  J Infect Dis       Date:  2000-10-26       Impact factor: 5.226

9.  Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot.

Authors:  M Finken; P Kirschner; A Meier; A Wrede; E C Böttger
Journal:  Mol Microbiol       Date:  1993-09       Impact factor: 3.501
View more
  9 in total

1.  The Resistant-Population Cutoff (RCOFF): a New Concept for Improved Characterization of Antimicrobial Susceptibility Patterns of Non-Wild-Type Bacterial Populations.

Authors:  Giorgia Valsesia; Michael Hombach; Florian P Maurer; Patrice Courvalin; Malgorzata Roos; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2015-03-11       Impact factor: 5.948

Review 2.  Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Authors:  Devan Jaganath; H Simon Schaaf; Peter R Donald
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

3.  Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis.

Authors:  Lukas Fenner; Matthias Egger; Thomas Bodmer; Ekkehardt Altpeter; Marcel Zwahlen; Katia Jaton; Gaby E Pfyffer; Sonia Borrell; Olivier Dubuis; Thomas Bruderer; Hans H Siegrist; Hansjakob Furrer; Alexandra Calmy; Jan Fehr; Jesica Mazza Stalder; Béatrice Ninet; Erik C Böttger; Sebastien Gagneux
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

4.  Defining multidrug-resistant tuberculosis: correlating GenoType MTBDRplus assay results with minimum inhibitory concentrations.

Authors:  Priti Kambli; Kanchan Ajbani; Meeta Sadani; Chaitali Nikam; Anjali Shetty; Zarir Udwadia; Sophia B Georghiou; Timothy C Rodwell; Antonino Catanzaro; Camilla Rodrigues
Journal:  Diagn Microbiol Infect Dis       Date:  2015-01-29       Impact factor: 2.803

5.  Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti.

Authors:  Kathleen F Walsh; Stalz Charles Vilbrun; Ariadne Souroutzidis; Sobieskye Delva; Guy Joissaint; Laurent Mathurin; Oksana Ocheretina; Pierre Cremieux; Jean William Pape; Serena P Koenig
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

6.  Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation.

Authors:  Burkhard Springer; Katja Lucke; Romana Calligaris-Maibach; Claudia Ritter; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2009-04-01       Impact factor: 5.948

7.  Performance Assessment of the BluePoint MycoID Plus Kit for Identification of Mycobacterium tuberculosis, Including Rifampin- and Isoniazid-resistant Isolates, and Nontuberculous Mycobacteria.

Authors:  Jung-Yien Chien; Tsung-Chain Chang; Wei-Yih Chiu; Chong-Jen Yu; Po-Ren Hsueh
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

8.  A Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, Russia.

Authors:  Elena Y Nosova; Danila V Zimenkov; Anastasia A Khakhalina; Alexandra I Isakova; Ludmila Y Krylova; Marina V Makarova; Ksenia Y Galkina; Maria A Krasnova; Svetlana G Safonova; Vitaly I Litvinov; Dmitry A Gryadunov; Elena M Bogorodskaya
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

9.  Minimal inhibitory concentrations of first-line drugs of multidrug-resistant tuberculosis isolates.

Authors:  Nicolas Schönfeld; Thorsten Bergmann; Silvan Vesenbeckh; Harald Mauch; Gudrun Bettermann; Torsten T Bauer; Holger Rüssmann
Journal:  Lung India       Date:  2012-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.